Antitumor activity and molecular mechanism of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Antitumor activity and molecular mechanism of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition
Authors
Keywords
-
Journal
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
Volume 395, Issue 6, Pages 643-658
Publisher
Springer Science and Business Media LLC
Online
2022-03-21
DOI
10.1007/s00210-022-02200-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The State of the Problem of Achieving Extremely Low LDL Levels
- (2021) Victoria Korneva et al. CURRENT PHARMACEUTICAL DESIGN
- Proprotein convertase subtilisin/kexin type 9 (PCSK9): A potential multifaceted player in cancer
- (2021) Anindita Bhattacharya et al. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
- PCSK9 and cancer: Rethinking the link
- (2021) Khadijeh Mahboobnia et al. BIOMEDICINE & PHARMACOTHERAPY
- PCSK9 is a promising prognostic marker in patients with advanced NSCLC
- (2020) Aldo Bonaventura et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Inhibition of proprotein convertase subtilisin/kexin type 9 attenuates 2,4,6‐trinitrobenzenesulfonic acid‐induced colitis via repressing toll‐like receptor 4/nuclear factor‐kappa B
- (2020) Lei Lei et al. KAOHSIUNG JOURNAL OF MEDICAL SCIENCES
- Cholesterol metabolism: New functions and therapeutic approaches in cancer
- (2020) Huanji Xu et al. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
- Pseurotin A as a novel suppressor of hormone dependent breast cancer progression and recurrence by inhibiting PCSK9 secretion and interaction with LDL receptor
- (2020) Khaldoun S. Abdelwahed et al. PHARMACOLOGICAL RESEARCH
- Colorectal Cancer in Inflammatory Bowel Disease
- (2020) Martina Nebbia et al. Clinics in Colon and Rectal Surgery
- PCSK9 Levels Are Raised in Chronic HCV Patients with Hepatocellular Carcinoma
- (2020) Silvano Fasolato et al. Journal of Clinical Medicine
- Structure and function of proprotein convertase subtilisin/kexin type 9 (PCSK9) in atherosclerosis
- (2019) Lei Zhang et al. CURRENT DRUG TARGETS
- Cholesterol Induces CD8+ T Cell Exhaustion in the Tumor Microenvironment
- (2019) Xingzhe Ma et al. Cell Metabolism
- Serum PCSK9 levels at the second nivolumab cycle predict overall survival in elderly patients with NSCLC: a pilot study
- (2019) Aldo Bonaventura et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Role of cholesterol homeostasis and its efflux pathways in cancer progression
- (2019) Bhoomika Sharma et al. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
- Assessing the Potential Risk of Cross-Reactivity Between Anti-Bococizumab Antibodies and Other Anti-PCSK9 Monoclonal Antibodies
- (2019) Ellen Q. Wang et al. BIODRUGS
- Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9
- (2019) Amand F. Schmidt et al. BMC Cardiovascular Disorders
- PCSK9 and inflammation: role of shear stress, pro-inflammatory cytokines, and LOX-1
- (2019) Zufeng Ding et al. CARDIOVASCULAR RESEARCH
- Long-Term Efficacy and Safety of Evolocumab in Patients With Hypercholesterolemia
- (2019) Michael J. Koren et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Could PCSK9 be a new therapeutic target of Eugenol? In vitro and in silico evaluation of hypothesis
- (2019) Saadiya Zia et al. MEDICAL HYPOTHESES
- PCSK9 inhibition alters the lipidome of plasma and lipoprotein fractions
- (2018) Mika Hilvo et al. ATHEROSCLEROSIS
- Hepatitis C virus regulates proprotein convertase subtilisin/kexin type 9 promoter activity
- (2018) Zhubing Li et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Cardiovascular Disease and Breast Cancer: Where These Entities Intersect: A Scientific Statement From the American Heart Association
- (2018) Laxmi S. Mehta et al. CIRCULATION
- PCSK9 inhibition in the management of familial hypercholesterolemia
- (2018) Masatsune Ogura Journal of Cardiology
- Proprotein convertase subtilisin/kexin type 9 inhibits hepatitis C virus replication through interacting with NS5A
- (2018) Zhubing Li et al. JOURNAL OF GENERAL VIROLOGY
- Hyperlipidemia: Management with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors
- (2018) Muhammed Shahreyar et al. Journal of the American Board of Family Medicine
- PCSK9 Inhibitors: Novel Therapeutic Strategies for Lowering LDL-Cholesterol
- (2018) Zhao-Peng Liu et al. MINI-REVIEWS IN MEDICINAL CHEMISTRY
- Proprotein Convertase Subtilisin-Kexin type-9 (PCSK9) and triglyceride-rich lipoprotein metabolism: Facts and gaps
- (2018) Andrea Baragetti et al. PHARMACOLOGICAL RESEARCH
- Primary brain tumours in adults
- (2018) Sarah Lapointe et al. LANCET
- A Mendelian randomization study of the effects of blood lipids on breast cancer risk
- (2018) Christoph Nowak et al. Nature Communications
- Inhibiting PCSK9 — biology beyond LDL control
- (2018) Robert M. Stoekenbroek et al. Nature Reviews Endocrinology
- PCSK9 and Atherosclerosis - Lipids and Beyond
- (2017) Michael D. Shapiro et al. Journal of Atherosclerosis and Thrombosis
- PCSK9 at the crossroad of cholesterol metabolism and immune function during infections
- (2017) Francesco Paciullo et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Safety of Very Low Low-Density Lipoprotein Cholesterol Levels With Alirocumab
- (2017) Jennifer G. Robinson et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- What is the impact of PCSK9 rs505151 and rs11591147 polymorphisms on serum lipids level and cardiovascular risk: a meta-analysis
- (2017) Chengfeng Qiu et al. Lipids in Health and Disease
- Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients
- (2017) Paul M Ridker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inhibition of PCSK9 protects against radiation-induced damage of prostate cancer cells
- (2017) Si-Shun Gan et al. OncoTargets and Therapy
- PCSK9 regulates apoptosis in human lung adenocarcinoma A549 cells via endoplasmic reticulum stress and mitochondrial signaling pathways
- (2017) Xiaohui Xu et al. Experimental and Therapeutic Medicine
- Actinidia chinensis Planch root extract inhibits cholesterol metabolism in hepatocellular carcinoma through upregulation of PCSK9
- (2017) Mingyan He et al. Oncotarget
- PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study
- (2017) Amand F Schmidt et al. Lancet Diabetes & Endocrinology
- PCSK9 signaling pathways and their potential importance in clinical practice
- (2017) Michał Wiciński et al. EPMA Journal
- Blood Lipid Concentrations and Colorectal Adenomas: A Systematic Review and Meta-Analysis of Colonoscopy Studies in Asia, 2000–2014
- (2016) Michael N. Passarelli et al. AMERICAN JOURNAL OF EPIDEMIOLOGY
- Lipid metabolism in critical illness
- (2016) Pnina Green et al. CURRENT OPINION IN CLINICAL NUTRITION AND METABOLIC CARE
- Safety and efficacy of LY3015014, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9): a randomized, placebo-controlled Phase 2 study
- (2016) John J.P. Kastelein et al. EUROPEAN HEART JOURNAL
- Possible involvement of PCSK9 overproduction in hyperlipoproteinemia associated with hepatocellular carcinoma: A case report
- (2016) Shuichi Nagashima et al. Journal of Clinical Lipidology
- Inflammatory processes in cardiovascular disease: a route to targeted therapies
- (2016) Neil Ruparelia et al. Nature Reviews Cardiology
- Hypocholesterolaemic Activity of Lupin Peptides: Investigation on the Crosstalk between Human Enterocytes and Hepatocytes Using a Co-Culture System Including Caco-2 and HepG2 Cells
- (2016) Carmen Lammi et al. Nutrients
- A retrospective study of NENs and miR-224 promotes apoptosis of BON-1 cells by targeting PCSK9 inhibition
- (2016) Jian’an Bai et al. Oncotarget
- Tumor-Induced Hyperlipidemia Contributes to Tumor Growth
- (2016) Jianfeng Huang et al. Cell Reports
- Alirocumab, a Therapeutic Human Antibody to PCSK9, Does Not Affect CD81 Levels or Hepatitis C Virus Entry and Replication into Hepatocytes
- (2016) Aarti Ramanathan et al. PLoS One
- Role of Insulin in the Regulation of Proprotein Convertase Subtilisin/Kexin Type 9Significance
- (2015) Ji Miao et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- The role of PCSK9 in intestinal lipoprotein metabolism: synergism of statin and ezetimibe
- (2015) Sergio Fazio ATHEROSCLEROSIS SUPPLEMENTS
- Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9)
- (2015) Rainer Schulz et al. BASIC RESEARCH IN CARDIOLOGY
- Cholesterol lowering: role in cancer prevention and treatment
- (2015) Toshiyuki Murai BIOLOGICAL CHEMISTRY
- Decreased PCSK9 expression in human hepatocellular carcinoma
- (2015) Mamatha Bhat et al. BMC GASTROENTEROLOGY
- Role of PCSK9 beyond liver involvement
- (2015) Bertrand Cariou et al. CURRENT OPINION IN LIPIDOLOGY
- Proprotein convertase subtilisin/kexin type 9 (PCSK9), soluble lectin-like oxidized LDL receptor 1 (sLOX-1) and ankle brachial index in patients with differentiated thyroid cancer
- (2015) Cigdem Ozkan et al. ENDOCRINE JOURNAL
- Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial
- (2015) Patrick M. Moriarty et al. Journal of Clinical Lipidology
- In vivo genome editing using Staphylococcus aureus Cas9
- (2015) F. Ann Ran et al. NATURE
- TLR4/NF-κB Signaling Contributes to Chronic Unpredictable Mild Stress-Induced Atherosclerosis in ApoE-/- Mice
- (2015) Ya Ling Tang et al. PLoS One
- Proprotein Convertase Subtilisin/Kexin Type 9 Deficiency Reduces Melanoma Metastasis in Liver
- (2015) Xiaowei Sun et al. NEOPLASIA
- Obesity, Cholesterol Metabolism, and Breast Cancer Pathogenesis
- (2014) D. P. McDonnell et al. CANCER RESEARCH
- Design and Synthesis of Truncated EGF-A Peptides that Restore LDL-R Recycling in the Presence of PCSK9 In Vitro
- (2014) Christina I. Schroeder et al. CHEMISTRY & BIOLOGY
- PCSK9
- (2014) Nabil G. Seidah et al. CIRCULATION RESEARCH
- Permanent Alteration of PCSK9 With In Vivo CRISPR-Cas9 Genome Editing
- (2014) Qiurong Ding et al. CIRCULATION RESEARCH
- Inhibition ofPCSK9Transcription by Berberine Involves Down-regulation of Hepatic HNF1α Protein Expression through the Ubiquitin-Proteasome Degradation Pathway
- (2014) Bin Dong et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Anti-PCSK9 Antibody Effectively Lowers Cholesterol in Patients With Statin Intolerance
- (2014) Erik Stroes et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- LDL CHOLESTEROL REDUCTION WITH BMS-962476, AN ADNECTIN INHIBITOR OF PCSK9: RESULTS OF A SINGLE ASCENDING DOSE STUDY
- (2014) Evan A. Stein et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Cancer-related inflammation and treatment effectiveness
- (2014) Connie I Diakos et al. LANCET ONCOLOGY
- Metabolic requirements for the maintenance of self-renewing stem cells
- (2014) Keisuke Ito et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Peptide-Based Anti-PCSK9 Vaccines - An Approach for Long-Term LDLc Management
- (2014) Gergana Galabova et al. PLoS One
- PCSK9 is a critical regulator of the innate immune response and septic shock outcome
- (2014) K. R. Walley et al. Science Translational Medicine
- PCSK9 plays a significant role in cholesterol homeostasis and lipid transport in intestinal epithelial cells
- (2013) Emile Levy et al. ATHEROSCLEROSIS
- Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Inhibitors in the Treatment of Hypercholesterolemia and other Pathologies
- (2013) Nabil G. Seidah CURRENT PHARMACEUTICAL DESIGN
- Identification of a Small Peptide That Inhibits PCSK9 Protein Binding to the Low Density Lipoprotein Receptor
- (2013) Yingnan Zhang et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Alterations in Gene Expression of Proprotein Convertases in Human Lung Cancer Have a Limited Number of Scenarios
- (2013) Ilya V. Demidyuk et al. PLoS One
- Targeting Toll-Like Receptors: Promising Therapeutic Strategies for the Management of Sepsis-Associated Pathology and Infectious Diseases
- (2013) Athina Savva et al. Frontiers in Immunology
- PCSK9 regulates neuronal apoptosis by adjusting ApoER2 levels and signaling
- (2012) Kai Kysenius et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Gene Inactivation of Proprotein Convertase Subtilisin/Kexin Type 9 Reduces Atherosclerosis in Mice
- (2012) Maxime Denis et al. CIRCULATION
- Cholesterol and prostate cancer
- (2012) Kristine Pelton et al. CURRENT OPINION IN PHARMACOLOGY
- PCSK9 siRNA suppresses the inflammatory response induced by oxLDL through inhibition of NF-κB activation in THP-1-derived macrophages
- (2012) ZHIHAN TANG et al. INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
- The PCSK9 decade
- (2012) Gilles Lambert et al. JOURNAL OF LIPID RESEARCH
- SILAC-based quantitative proteomic analysis of gastric cancer secretome
- (2012) Arivusudar Marimuthu et al. Proteomics Clinical Applications
- Role of Cholesterol in the Development and Progression of Breast Cancer
- (2011) Gemma Llaverias et al. AMERICAN JOURNAL OF PATHOLOGY
- Glioma Stem Cell Proliferation and Tumor Growth Are Promoted by Nitric Oxide Synthase-2
- (2011) Christine E. Eyler et al. CELL
- Migration of MDA-MB-231 breast cancer cells depends on the availability of exogenous lipids and cholesterol esterification
- (2011) Caryl J. Antalis et al. CLINICAL & EXPERIMENTAL METASTASIS
- PCSK9 LNA Antisense Oligonucleotides Induce Sustained Reduction of LDL Cholesterol in Nonhuman Primates
- (2011) Marie W Lindholm et al. MOLECULAR THERAPY
- Ezetimibe and Vascular Endothelial Function
- (2010) Satoshi Ikeda et al. Current Vascular Pharmacology
- A Locked Nucleic Acid Antisense Oligonucleotide (LNA) Silences PCSK9 and Enhances LDLR Expression In Vitro and In Vivo
- (2010) Nidhi Gupta et al. PLoS One
- Regulation of the proprotein convertase subtilisin/kexin type 9 in intestinal epithelial cells
- (2009) François Leblond et al. AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
- Proprotein Convertase Subtilisin Kexin Type 9 Null Mice Are Protected From Postprandial Triglyceridemia
- (2009) Cédric Le May et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Monoacylglycerol Lipase Regulates a Fatty Acid Network that Promotes Cancer Pathogenesis
- (2009) Daniel K. Nomura et al. CELL
- PCSK9-deficient mice exhibit impaired glucose tolerance and pancreatic islet abnormalities
- (2009) Majambu Mbikay et al. FEBS LETTERS
- PCSK9 impedes hepatitis C virus infectionin vitroand modulates liver CD81 expression
- (2009) Patrick Labonté et al. HEPATOLOGY
- Colorectal cancer in inflammatory bowel disease
- (2009) Rupert W L Leong et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Inflammation stimulates the expression of PCSK9
- (2008) Kenneth R. Feingold et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Proprotein convertase subtilisin/kexin type 9 (PCSK9): Hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration
- (2008) Ahmed Zaid et al. HEPATOLOGY
- Genome-wide expression analysis of cells expressing gain of function mutant D374Y-PCSK9
- (2008) Trine Ranheim et al. JOURNAL OF CELLULAR PHYSIOLOGY
- PCSK9: a convertase that coordinates LDL catabolism
- (2008) Jay D. Horton et al. JOURNAL OF LIPID RESEARCH
- Molecular basis for LDL receptor recognition by PCSK9
- (2008) H. J. Kwon et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates
- (2008) M. Frank-Kamenetsky et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started